AVENUE THERAPEUTICS INC (ATXI)

Company Profile

Avenue Therapeutics, Inc. is a specialty pharmaceutical company, which engages in acquiring, licensing, and commercializing products for use in the intensive care hospital setting. The company is headquartered in Bay Harbor Islands, Florida and currently employs 2 full-time employees. The company went IPO on 2017-06-27. The firm is focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. The Company’s product candidates include AJ201 for the treatment of spinal and bulbar muscular atrophy (SBMA), intravenous (IV) Tramadol (IV Tramadol) for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. AJ201 is in a Phase 1b/2a clinical trial in the United States. AJ201 is designed to modify SBMA through multiple mechanisms including degradation of the abnormal AR protein and by stimulating Nrf1 and Nrf2, which are involved in protecting cells from oxidative stress, which can lead to cell death. Through its subsidiary, Baergic Bio, Inc. (Baergic), it is developing BAER-101, a high affinity, selective modulator of the gamma-aminobutyric acid (GABA).

Company Info

AVENUE THERAPEUTICS INC

1111 Kane Concourse, Suite 301

Bay Harbor Islands FLORIDA 10036

P: 17816524500

CEO: Lucy Lu

Employees: 2

Website: https://avenuetx.com/